AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04329429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48-ADC
Description: The eligible patients will be treated with RC48-ADC, an antibody-drug conjugate, 2.5 mg/kg, once every two weeks until investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first)
Study NCT00405418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Description: Subcutaneous injection, once a day in the evening
Study NCT00405418 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Detemir
Description: Subcutaneous injection, twice a day at breakfast and before dinner
Study NCT04204161 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T19/CAR-T22
Description: According to tumor burden and other conditions, patients will be treated with cyclophosphamide or fludarabine,then,CAR-T cells will be infused 48-72 hours later.The recommand dose is 1x10\^5/kg-2.5x10\^8/kg .
Study NCT03358550 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Accommodation Measurement
Description: Accommodation was measured for different distances and light conditions.
Study NCT03764514 — intervention group
Intervention type: DEVICE
Intervention: Spinal Cord Stimulator
Description: Permanent Implantation
Study NCT03871530 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coordinate A
Description: PIEB Next Bolus: 45 minutes, PIEB Interval: 50 minutes, and PIEB volume: 5 mL
Study NCT03871530 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coordinate B
Description: PIEB Next Bolus: 45 minutes, PIEB Interval: 40 minutes, and PIEB volume: 6.5 mL
Study NCT03871530 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coordinate C
Description: PIEB Next Bolus: 45 minutes, PIEB Interval: 50 minutes, and PIEB volume: 8 mL
Study NCT03871530 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coordinate D
Description: PIEB Next Bolus: 45 minutes, PIEB Interval: 60 minutes, and PIEB volume: 6.5 mL
Study NCT03871530 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coordinate E
Description: PIEB Next Bolus: 30 minutes, PIEB Interval: 40 minutes, and PIEB volume: 5 mL
Study NCT00872209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.3% Ciprofloxacin Ear Drops
Description: 4 gtt BID for 7 days.
Study NCT00872209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.3% Ciprofloxacin Foam Otic Cipro
Description: 1 application, BID for 7 days
Study NCT02849613 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adipose Derived Stem Cells
Study NCT02849613 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Vehicle media
Study NCT04566562 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Brain Imaging
Description: Magnetic Resonance Imaging (MRI) using diffusion weighted pseudo-continuous arterial spin labeling (DW-pCASL) .
Study NCT04566562 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cognitive Testing
Description: Wide Range Assessment of Memory and Learning (WRAML 2) and Montreal Cognitive Assessment (MoCA)
Study NCT04566562 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Biomarkers
Description: Inflammatory Markers
Study NCT03871530 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coordinate F
Description: PIEB Next Bolus: 30 minutes, PIEB Interval: 40 minutes, and PIEB volume: 8 mL
Study NCT03871530 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coordinate G
Description: PIEB Next Bolus: 30 minutes, PIEB Interval: 60 minutes, and PIEB volume: 8 mL
Study NCT03871530 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coordinate H
Description: PIEB Next Bolus: 30 minutes, PIEB Interval: 60 minutes, and PIEB volume: 5 mL
Study NCT03871530 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coordinate I
Description: PIEB Next Bolus: 15 minutes, PIEB Interval: 50 minutes, and PIEB volume: 5 mL
Study NCT04291053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huaier Granule
Description: standard treatment + Huaier Granule 20g po tid for 2weeks
Study NCT00809367 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Collection of Leukemia Cells
Description: Collection of leukemia cells either by 1) routine blood draw 2) bone marrow aspirate or 3) leukopheresis
Study NCT02088957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam intravenous solution
Description: * Active Substance: Brivaracetam~* Pharmaceutical Form: Solution for infusion~* Concentration: 10 mg/mL~* Route of Administration: Intravenous bolus use
Study NCT02088957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam oral tablets
Description: * Active Substance: Brivaracetam~* Pharmaceutical Form: Film-coated tablet~* Concentration: 10 mg and 25 mg tablets; Daily Dose: 200 mg/day (100 mg bid)~* Route of Administration: Oral use
Study NCT02088957 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenytoin intravenous solution
Description: * Active Substance: Phenytoin~* Pharmaceutical Form: Solution for infusion~* Concentration: 50 mg/mL~* Route of Administration: Intravenous use
Study NCT02088957 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenytoin oral tablets
Description: * Active Substance: Phenytoin~* Pharmaceutical Form: Tablet~* Concentration: Weight based~* Route of Administration: Oral use
Study NCT01523067 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vasomera (PB1046)
Description: Single dose of Vasomera
Study NCT01523067 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride
Description: Placebo injection
Study NCT00512655 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fall prevention course
Description: Duration: 5 weeks, 2 sessions of 2 hours per week: 10 sessions in total.
Study NCT02071290 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pneumatic tourniquet
Description: Four cycles of brief occlusion of bloodflow to the thigh (5 minutes) followed by reperfusion (5 minutes) using a pneumatic tourniquet~Remote Ischemic Conditioning
Study NCT02071290 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Pneumatic tourniquet
Description: Four cycles of brief occlusion of bloodflow to the thigh (5 minutes) followed by reperfusion (5 minutes) using a pneumatic tourniquet~Remote Ischemic Conditioning
Study NCT02906826 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Video game
Description: Video game operated by performing therapy correctly
Study NCT03215862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactated Ringer
Description: This is a Lactated Ringer's solution infusion before, during, and after the ERCP procedure.
Study NCT03215862 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline 0.9% Infusion Solution Bag
Description: This is a Normal Saline solution infusion before, during, and after the ERCP procedure.
Study NCT02370264 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02370264 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02370264 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Chart Review
Description: Ancillary studies
Study NCT03871530 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coordinate J
Description: PIEB Next Bolus: 15 minutes, PIEB Interval: 40 minutes, and PIEB volume: 6.5 mL
Study NCT03338296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lorcaserin hydrochloride XR
Description: oral tablet
Study NCT03338296 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablet
Study NCT00868153 — intervention group
Intervention type: DRUG
Intervention: Levonorgestrel IUS (Mirena , BAY86-5028)
Description: One group
Study NCT04578353 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The AquaPass System
Description: The AquaPass device is a capsule that creates relatively homogenous temperature around the patients' lower body, while controlling and maintaining at a low percentage the relative humidity within the capsule thus enabling controlled environment that enhances sweat rate.
Study NCT01741805 — intervention group
Intervention type: OTHER
Intervention: Severe Asthma
Description: Demographic data, Spirometry, induced sputum, IgE, Aspergillus specific IgE
Study NCT00874731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ridaforolimus 100 mg
Description: Part 1: A single oral dose of 100 mg ridaforolimus (10 x 10 mg tablets) was given on Day 2.
Study NCT00874731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ridaforolimus 40 mg
Description: Part 2 (optional): Ridaforolimus 40 mg (4 x 10 mg tablets) was received on a regimen of daily oral doses for 5 consecutive days followed by 2 days off-drug.
Study NCT00874731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Part 1: A single oral dose of placebo (10 x placebo tablets) was given on Day 1.
Study NCT00458081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimonabant
Description: 20 mg once per day + slightly reduced calorie diet
Study NCT00458081 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo once per day + slightly reduced calorie diet
Study NCT00002622 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: talc
Description: 4 to 5 grams talc in 100 cc saline via chest tube at bedside, one time
Study NCT00002622 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Talc
Description: 4 to 5 grams talc via insufflation through direct or video thoracoscopy, one time
Study NCT00953186 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: hyperbaric air
Description: air at 2,5 atmospheres for 90 minutes/day, 5 days a week for 8 weeks treatment given in hyperbaric chamber
Study NCT00953186 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HBOT
Description: 100 % oxygen at 2,5 atmospheres for 90 minutes/day, 5 days a week for 8 weeks treatment given in hyperbaric chamber
Study NCT02175641 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-Led Group Lifestyle Balance
Description: The intervention follows the Group Lifestyle Balance curriculum derived from the Diabetes Prevention Program and The intervention will be delivered by trained peer-specialists employed at the supportive housing agencies and supervised by the study team. Peer GLB is a 12-month group intervention that focuses helping people lose weight by improving people's diet and increasing their physical activity and consists of weekly core group sessions (3 mo.), bi-monthly transitional group sessions (3 mo.), and maintenance monthly sessions (6 mo.).
Study NCT02175641 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care Services
Description: The usual care condition encompasses the regular services offered at supportive housing agencies to help clients with their physical health and wellness.
Study NCT02175641 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Services
Description: The usual care condition encompasses the regular services offered at supportive housing agencies to help clients with their physical health and wellness.
Study NCT03822975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Description: Bivaliruding 0.75 mg/kg intravenous bolus loading dose, and immediately followed by intravenous infusion of 1.75 mg/kg/h until 2-4 hours after PCI. It is recommended that ACT be monitored 5 minutes after the first administration, and if ACT is \<225 s (Hemotec method), intravenous injection of 0.35 mg/kg of bivalirudin should be administered, and the ACT re-checked to ensure it is >225 seconds.
Study NCT03822975 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: unfractionated Heparin
Description: Heparin 70 U/kg is started before coronary angiography. ACT is monitored 5 min after the first administration, and if the ACT \<225 s (Hemotec method), an intravenous injection of 1000 U of heparin is administered, and the ACT re-checked to ensure it is >225 seconds.
Study NCT01076777 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: Manualised Exercise performed in groups (5-8 participants per group). 3 sessions (á 60 minutes) per week for 12 consecutive weeks
Study NCT01076777 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-behavioral therapy
Description: Cognitive-behavioral therapy conducted in groups (5-8 participants per group). 1 session (á 2-2.25 hours depending on group size) per week for 12 consecutive weeks
Study NCT00479882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: simvastatin
Study NCT03871530 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coordinate K
Description: PIEB Next Bolus: 15 minutes, PIEB Interval: 50 minutes, and PIEB volume: 8 mL
Study NCT03871530 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coordinate L
Description: PIEB Next Bolus: 15 minutes, PIEB Interval: 60 minutes, and PIEB volume: 6.5 mL
Study NCT03871530 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coordinate M
Description: PIEB Next Bolus: 30 minutes, PIEB Interval: 50 minutes, and PIEB volume: 6.5 mL
Study NCT03871530 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coordinate N
Description: PIEB Next Bolus: 30 minutes, PIEB Interval: 50 minutes, and PIEB volume: 6.5 mL
Study NCT00292552 — intervention group
Intervention type: OTHER
Intervention: Novel endpoint determination
Description: Novel endpoint determination
Study NCT05380154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin A type for injection (Botulax®)
Description: Person in charge of dilution uses 0.9% sodium chloride injection solution to formulate the drug substance into 4U/0.1mL composite solution, and the investigator injects it into the test subjects
Study NCT05380154 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin A type for injection (BOTOX®, Bao Tuo Shi®)
Description: Person in charge of dilution uses 0.9% sodium chloride injection solution to formulate the drug substance into 4U/0.1mL composite solution, and the investigator injects it into the test subjects.
Study NCT01715233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Modified Docetaxel 40mg/m2 on Day 1
Study NCT01715233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Leucovorin 400mg/m2 on Day 1
Study NCT00479882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0524A
Description: Extended-release(ER) niacin/Laropiprant (MK-0524) Combination tablet
Study NCT01715233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Fluorouracil 400mg/m2 on Day 1 Fluorouracil 1000mg/m2/day on Days 1 and 2
Study NCT01715233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin (or Carboplatin) 40mg/m2 on Day 3
Study NCT00479882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT00479882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0524B
Study NCT00523640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combination of gemcitabine, capecitabine, and bevacizumab
Description: gemcitabine 1000 mg/m\^2 d1, 8, capecitabine 1000 mg (flat dose) po bid d1-14, and bevacizumab 15 mg/kg d 1, on a 21 day cycle
Study NCT03969368 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rPMS device
Description: Pelvic floor muscle contractions will be induced by the rPMS device.
Study NCT03969368 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor muscle training
Description: Control group will undergo a pelvic floor muscle training
Study NCT02212353 — intervention group
Intervention type: OTHER
Intervention: Observational study, not interventional
Study NCT03982251 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High frequency whole body vibration
Description: 1 single session ( 8 minutes) of whole body vibration therapy at 30 Hz
Study NCT03982251 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Low frequency whole body vibration
Description: 1 single session ( 12 minutes) of whole body vibration therapy at 20 Hz
Study NCT03254043 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Take-home Dosing Procedures
Description: Within-subject evaluation across 2 phases with a final choice condition
Study NCT03254043 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Take-home Dosing Procedures
Description: Within-subject evaluation across 2 phases with a final choice condition
Study NCT03254043 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Take-home Dosing Procedures
Description: Within-subject evaluation across 2 phases with a final choice condition
Study NCT01419470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapoxetine
Description: 1. multiple dosing~2. 12 subjects will be administered YHD1044 (I, III, V) or active/placebo comparators;dapoxetine
Study NCT02026492 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exercise challenge in a cold chamber
Description: Exercise challenge is defined as running on a treadmill for 6-8 minutes on submaximal work load in a cold chamber.
Study NCT02026492 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Methacholine challenge
Description: nebulized metacholine administered at following doses: 0,01mg, 0,1mg, 0,4mg, 0,8mg und 1,6mg
Study NCT02026492 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exercise challenge in room temperature
Description: Exercise challenge is defined as running on a treadmill for 6-8 minutes on submaximal work load in room temperature.
Study NCT04659564 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: User of Dayspring device
Description: The Dayspring™ device is a novel FDA-cleared wearable solution that is portable and easy-to-use sequential compression system.
Study NCT03811613 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial photobiomodulation
Description: Photobiomodulation was administered using red light-emitting diodes (LEDs) with a 670-nm wavelength (which has proven to penetrate the skull)
Study NCT03811613 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Transcranial photobiomodulation
Description: Photobiomodulation was administered using red light-emitting diodes (LEDs) with a 670-nm wavelength (which has proven to penetrate the skull)
Study NCT03683836 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: No intervention
Description: No intervention
Study NCT04153279 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMV-TCR-T cells
Description: Patients with CMV emias or CMV disease will be enrolled, and donor derived CMV-TCR-T(HLA-A\*1101\\0201\\2402) cells will be intravenously infused with a escalated dose of 0.1-1×106 CMV-TCR-T cells. The CMV DNA copies and CMV-TCR-T cell proliferation will be monitored in the scheduled time (day 0, day 4, day 7, day 10, day 14,day 28).
Study NCT02262910 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ES414
Description: ES414 is a novel humanized bispecific antibody which is designed to treat mCRPC by redirecting T-cell cytotoxicity against prostate cancer cells expressing prostate-specific membrane antigen (PSMA).
Study NCT00535652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertapenem
Description: powder for infusion, 1 gram I.V., single dose over 30 min.
Study NCT02799017 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive Phonology Treatment
Description: Phonology based reading, writing, and naming therapy.
Study NCT02799017 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intensive SFA Treatment
Description: Semantic based reading, writing, and naming therapy.
Study NCT04605640 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Management Intervention
Description: Participants attend group and individual dietary education sessions. Participants create a diet plan that satisfies their needs. Participants aim to lose 1 pound weekly until a BMI of 25 is reached. Participants are evaluated through daily self-weighing, dietary records, and food frequency questionnaires.
Study NCT01734239 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumovax™ 23
Description: Vaccine contains 25 µg of each of the 23 pneumococcal polysaccharides serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F
Study NCT03882177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: Tablets, administered orally
Study NCT03882177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifafour
Description: Fixed-dose combination (isoniazid, rifampin, pyrazinamide, and ethambutol) tablets, administered orally
Study NCT03882177 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B6
Description: Administered orally.
Study NCT02035618 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercises
Description: Strengthening and stretching
Study NCT02035618 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises
Description: Strengthening and stretching